Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21775412 | 0.76 | CA1 (0.31) | CA1CA2 | |
| SCHEMBL871344 | 0.73 | DRD3 (0.35) | GRM5 | |
| SCHEMBL18202836 | 0.72 | USP30 (0.33) | — | |
| SCHEMBL18975940 | 0.70 | — | — | |
| SCHEMBL1546827 | 0.69 | POLB (0.87) | POLBKMT2ATSHRKDM4EALDH1A1 | |
| SCHEMBL20527949 | 0.68 | TSHR (0.36) | POLBTSHRKDM4EALDH1A1LMNA | |
| SCHEMBL5280013 | 0.67 | POLB (0.93) | POLBKMT2ATSHRKDM4EALDH1A1 | |
| SCHEMBL29905605 | 0.67 | POLB (0.93) | POLBKMT2ATSHRKDM4EALDH1A1 | |
| SCHEMBL20527980 | 0.67 | EPHX2 (0.31) | — | |
| SCHEMBL21775400 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11045455-B2 | Azetidine derivative, preparation method therefor, and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-06-29 | — | — | US | disclosed |
| US-11045455-B2 | Azetidine derivative, preparation method therefor, and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-06-29 | — | — | US | disclosed |
| EP-3360878-B9 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2021-05-05 | — | — | EP | disclosed |
| EP-3360878-B9 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2021-05-05 | — | — | EP | disclosed |
| EP-3360878-B1 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2020-09-16 | — | — | EP | disclosed |
| EP-3360878-B1 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2020-09-16 | — | — | EP | disclosed |
| US-20200147062-A1 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-05-14 | — | — | US | disclosed |
| US-20200147062-A1 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-05-14 | — | — | US | disclosed |
| US-10159662-B2 | Azetidine derivative, preparation method therefor, and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2018-12-25 | — | — | US | disclosed |
| US-20180289680-A1 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2018-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11045455-B2 | Azetidine derivative, preparation method therefor, and use thereof | JAK1, JAK2, JAK3 | POLB 3926/4885KMT2A 1318/4885TSHR 3158/4885 |
| US-20200147062-A1 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | JAK1, JAK2, JAK3 | POLB 3926/4885KMT2A 1318/4885TSHR 3158/4885 |
| US-10159662-B2 | Azetidine derivative, preparation method therefor, and use thereof | JAK1, JAK2, JAK3 | POLB 3926/4885KMT2A 1318/4885TSHR 3158/4885 |
| US-20180289680-A1 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | JAK1, JAK2, JAK3 | POLB 3926/4885KMT2A 1318/4885TSHR 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.